BioTech
-
Health care spending will be boosted by Ozempic-like drugs, reports find
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they’re set to cost the U.S. health care…
Read More » -
Novo Nordisk to discontinue Levemir, insulin patients left hanging
A year ago, when Novo Nordisk announced it would cut the price of multiple insulin products by up to 75%,…
Read More » -
FDA gives nod to Day One’s drug for common childhood brain tumor
Day One Biopharmaceuticals said Tuesday the Food and Drug Administration approved its pill for one of the most common forms…
Read More » -
Readout newsletter: CRISPR, Biogen, GLP-1 drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Readout Newsletter: Novo Nordisk, antibiotics, Duchenne
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Readout LOUD podcast: New obesity startup, future of Teledoc
How does a startup compete with the likes of Eli Lilly and Novo Nordisk in the rapidly evolving field of…
Read More » -
Metsera comes out of stealth with $290 million for obesity drugs
After scouring 200 companies’ pipelines — including a few overlooked pharma shelves — a new company backed by investment firm…
Read More » -
a frenzied push into autoimmune disease
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to…
Read More » -
23andme CEO Anne Wojcicki moves to take company private
After a tumultuous experience on the public markets, 23andMe CEO Anne Wojcicki is moving to take the company private. Wojcicki…
Read More » -
Cancer vaccine startup launches with $54 million, Spark veteran as CEO
A new startup focused on creating vaccines for cancers, influenza, and potentially even HIV launched Thursday with $54 million in…
Read More »